S-1 as first-line treatment for advanced gastric cancer

doi:10.3760/cma.j.issn.1673-422X.2014.03.016

Abstract

Abstract: Patients with advanced gastric cancer lose the surgical indications. Chemotherapy can improve the overall survival and quality of life, which is the main treatment option. But there is no standard chemotherapy regimen for the patients with advanced gastric cancer. Since its initial approval, S-1 is widely used in gastric cancer. Several studies were performed to explore combinations of S-1 with other cytotoxic drugs such as platinum, docetaxel, paclitaxel, and irinotecan. All these combinations were found to be promising, with response rates of around 40%-50% and relatively favorable safety profiles.

Key words: Stomach neoplasms, Drug therapy, S-1

JIANG Feng-E, SUN Ping. S-1 as first-line treatment for advanced gastric cancer[J]. Journal of International Oncology, 2014, 41(3): 211-213.

References

［1］吴春晓，郑莹，鲍萍萍，等. 上海市胃癌发病流行现况与时间趋势分析［J］. 外科理论与实践, 2008, 13(1):2429. ［2］ Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S1 in metastatic gastric cancer: a randomised phase 3 study［J］. Lancet Oncol, 2009, 10(11):10631069. ［3］ Imamura H, Kishimoto T, Takiuchi H, et al. Phase II study of S1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404)［J］. J Chemother, 2013, 15(8):13361341. ［4］ Koizumi W, Narahara H, Hara T, et al. S1 plus cisplatin versus S1 alone for firstline treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial［J］. Lancet Oncol, 2008, 9(3):215221. ［5］ Ajani JA, Rodriguez W, Bodoky G, et al. Multicenter phase III comparison of cisplatin/S1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial［J］. J Clin Oncol, 2010, 28(9):15471553. ［6］ Ajani JA, Buyse M, Lichinitser M. Combination of cisplatin/S1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5fluorouracil in the FirstLine Advanced Gastric Cancer Study［J］. Eur J Cancer, 2013, 49(17):36163624. ［7］ Koizumi W, Takiuchi H, Yamada Y, et al. Phase II study of oxaliplatin plus S1 as firstline treatment for advanced gastric cancer (GSOX study)［J］. Ann Oncol, 2010, 21(5):10011005. ［8］ Yang L, Song Y, Zhou AP, et al. A phase Ⅱ trial of oxaliplatin plus S1 as a firstline chemotherapy for patients with advanced gastric cancer［J］. Chin Med J(Engl), 2013, 126(18): 34703474. ［9］ Kim GM, Jeung HC, Rha SY, et al. A randomized phase II trial of S1oxaliplatin versus capecitabineoxaliplatin in advanced gastric cancer［J］. Eur J Cancer, 2012, 48(4):518526. ［10］ Shuichi Hironaka, Kentaro Yamazaki, Keisei Taku, et al. Phase I Study of Docetaxel, Cisplatin and S1 in Patients with Advanced Gastric Cancer［J］. Jpn J Clin Oncol, 2010, 40(11):10141020. ［11］ Kunisaki C, Takahashi M, Makino H, et al. Phase Ⅱ study of biweekly docetaxel and S1 combination chemotherapy as firstline treatment for advanced gastric cancer［J］. Cancer Chemother Pharmacol, 2011, 67(6): 13631368. ［12］ Cui Y, Li Q, Yu Y, Chen Y, et al. Combination of lowdose docetaxel and standarddose S1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor［J］. Cancer Chemother Pharmacol, 2013, 71(1):145152. ［13］ Kunisaki C, Takahashi M, Ono HA, et al. Biweekly Docetaxel and S1 combination chemotherapy as firstline treatment for elderly patients with advanced gastric cancer［J］. Anticancer Res, 2013, 33(2):697704. ［14］ Narahara H, Ishii H, Imamura H, et al. Randomized phase Ⅲ study comparing the efficacy and safety of irinotecan plus S1 with S1 alone as firstline treatment for advanced gastric cancer (study GC0301/TOP002)［J］. Gastric Cancer, 2011, 14(1):7280. ［15］ Park SR, Kong SY, Rhee J, et al. Phase Ⅱ study of a triplet regimen of S1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results［J］. Ann Oncol， 2011, 22(4):890896.

[1]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[4]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[5]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[6]	Yue Hongyun, Zhang Baihong. Differentiation therapies in human cancers [J]. Journal of International Oncology, 2024, 51(2): 109-113.
[7]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[8]	Shao Huifang, Wang Xuehong, Lu Yongfu. Mechanism of action and clinical significance of CST1 in the progression of gastric cancer [J]. Journal of International Oncology, 2023, 50(8): 489-492.
[9]	Zhu Siyu, Wang Xuehong, Li Wenqian, Liu Shu. Level of serum FABP1 and its relationship with Helicobacter pylori infection in patients with gastric cancer [J]. Journal of International Oncology, 2023, 50(6): 336-341.
[10]	Li Chenxi, Zhao Hongwei. Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery [J]. Journal of International Oncology, 2023, 50(6): 342-347.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Quan Zhenhao, Xu Feipeng, Huang Zhe, Huang Xianjin, Chen Rihong, Sun Kaiyu, Hu Xu, Lin Lin. lncRNA FTX silencing inhibits gastric cancer cell proliferation through the miR-22-3p/NLRP3 inflammasome pathway [J]. Journal of International Oncology, 2023, 50(4): 202-207.
[13]	Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer [J]. Journal of International Oncology, 2023, 50(3): 183-185.
[14]	Fan Shanlin, Wang Pinxiu, Kong Fei, Zhou Yujie, Yuan Wenzhen. Progress in the study of predictors of tumor regression grade after neoadjuvant chemotherapy for gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 112-116.
[15]	Yang Jun, Li Rong, Zeng Jianchang. Clinical efficacy of Compound Kushen Injection combined with SOX regimen in the treatment of elderly patients with advanced gastric cancer [J]. Journal of International Oncology, 2023, 50(2): 82-86.